Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2691-2698

  Bejar, Rafael ^a   Stevenson, Kristen E ^b   Caughey, Bennett ^a   Lindsley, R Coleman ^b,c   Mar, Brenton G ^b   Stojanov, Petar ^d   Getz, Gad ^d   Steensma, David P ^b   Ritz, Jerome ^b   Soiffer, Robert ^b   Antin, Joseph H ^b   Alyea, Edwin ^b   Armand, Philippe ^b   Ho, Vincent ^b   Koreth, John ^b   Neuberg, Donna ^b   Cutler, Corey S ^b   Ebert, Benjamin L ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; DNA METHYLTRANSFERASE 3A; MEMBRANE PROTEIN; PROTEIN P53; TET2 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME ABERRATION; DISEASE ASSOCIATION; DNA SEQUENCE; FEMALE; GENE SEQUENCE; GENETIC CODE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; TREATMENT OUTCOME; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROCEDURES; PROGNOSIS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906809218     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.3381     Document Type: Article

References (33)

1. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
2. Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465, 2012
3. Bejar R, Stevenson K, Abdel-Wahab O, et al: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506, 2011
4. Papaemmanuil E, Cazzola M, Boultwood J, et al: Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365:1384-1395, 2011
5. Papaemmanuil E, Gerstung M, Malcovati L, et al: Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122: 3616-3627, 2013
6. Walter MJ, Shen D, Shao J, et al: Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27:1275-1282, 2013
7. Haferlach T, Nagata Y, Grossmann V, et al: Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241-247, 2014
8. Itzykson R, Kosmider O, Cluzeau T, et al: Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25:1147-1152, 2011
9. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004
10. Deeg HJ, Scott BL, Fang M, et al: Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 120:1398-1408, 2012
11. Koreth J, Pidala J, Perez WS, et al: Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An international collaborative decision analysis. J Clin Oncol 31:2662-2670, 2013
12. Armand P, Kim HT, Cutler CS, et al: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586-4588, 2007
13. Lim ZY, Fiaccadori V, Gandhi S, et al: Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res 34:723-727, 2010
14. Saber W, Cutler CS, Nakamura R, et al: Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood 122:1974-1982, 2013
15. Li H, Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26:589-595, 2010
16. DePristo MA, Banks E, Poplin R, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491-498, 2011
17. Cibulskis K, Lawrence MS, Carter SL, et al: Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31:213-219, 2013
18. Smith AE, Mohamedali AM, Kulasekararaj A, et al: Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals lowabundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116: 3923-3932, 2010
19. Bejar R, Stevenson KE, Caughey BA, et al: Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30:3376-3382, 2012
20. Yoshida K, Sanada M, Shiraishi Y, et al: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-69, 2011
21. Kulasekararaj AG, Smith AE, Mian SA, et al: TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 160:660-672, 2013
22. Thol F, Friesen I, Damm F, et al: Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499-2506, 2011
23. Graubert TA, Shen D, Ding L, et al: Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 44:53-57, 2012
24. Thol F, Kade S, Schlarmann C, et al: Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119:3578-3584, 2012
25. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2011
26. Cancer Genome Atlas Research Network: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059-2074, 2013
27. Thol F, Winschel C, Lüdeking A, et al: Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 96:1870-1873, 2011
28. Walter MJ, Ding L, Shen D, et al: Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:1153-1158, 2011
29. Kaneko H, Misawa S, Horiike S, et al: TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85:2189-2193, 1995
30. Kita-Sasai Y, Horiike S, Misawa S, et al: International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 115:309-312, 2001
31. Horiike S, Kita-Sasai Y, Nakao M, et al: Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leuk Lymphoma 44:915-922, 2003
32. Jädersten M, Saft L, Smith A, et al: TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 29:1971-1979, 2011
33. Ho VT, Vanneman M, Kim H, et al: Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 106: 15825-15830, 2009 Kidney Diseases